[Treatment of excretory azoospermia. Biological aspects of surgery].

The therapeutical strategy for excretory azoospermia is very efficient at the present time. It is represented by two complementary methods very different both in their concept and their practical aspects. The surgery for recanalisation of the seminal tract is the old method, associated with reproducible and validated results providing a sophisticated operative methodology which implies microsurgery.

[Therapeutic hopes in excretory azoospermia and genetic risks in congenital aplasia of the vas deferens].

Therapeutical solutions now can be proposed to some excretory azoospermia, using in vitro-fertilization with epididymal sperm. The encouraging results obtained with this new approach should be analyzed with the genetic risk, sometimes encountered in the specific form of azoospermia due to the congenital absence of the vas deferens. This abnormality is to day supposed to represent a moderate form of cystic fibrosis (CF), corresponding to a genital phenotype of this disease.

[25 patients undergoing laparoscopy for pelvic pain].

25 patients have involved in this research, who have chronic gynecologic pelvic pain and each of them had normal gynecologic examination. Chronic pelvic pain has been found mostly between 30-39 years age group married, multipar females, associated with 44% dysmenorrhea, 36 p. cent dyspareunaie.

Motility and fertilizing capacity of epididymal human spermatozoa in normal and pathological cases.

Objective: To investigate different factors involved in the outcome of in vitro fertilization (IVF) with epididymal spermatozoa in cases of vas deferens agenesis, with particular emphasis on sperm movement parameters.

Design: Prospective study in which sperm movement characteristics, level of puncture, and sperm preparation technique were studied relative to the outcome of IVF.

Setting: Département de Gynécologie, Oncologie Gynécologique, Sénologie, Médecine de la Reproduction, Hôpital Edouard-Herriot, Lyon France.

[Infections by Mycoplasma hominis and Ureaplasma urealytycum in vaginal discharge. Incidence and treatment].

This report summarizes the studies carried out on 100 patients who were examined for vaginal discharge. The following observations were made: Mycoplasma hominis in 13.59% of the cases, Ureaplasma urealytycum in 8.